The main measure for the prevention and treatment of diabetic neuropathy is achieving and maintaining target glycemic values. Recommendations for the pathogenetic therapy of diabetic neuropathy (benfotiamine, aldolase reductase inhibitors, thioctic acid, nerve growth factor, aminoguanidine, protein kinase C inhibitor) are undergoing development.